Ilhan O, et al. - The efficacy and toxicity of autologous hematopoietic cell transplantation (auto HSCT) in patients >60 years with non-Hodgkin's lymphoma (NHL) were investigated. From the Ankara University Faculty of Medicine, Department of Hematology and Bone Marrow Transplant Unit, researchers evaluated data from 29 patients (M/F: 21/8; median age: 63 years) with aggressive NHL above 60 years of age who were eligible for auto HSCT according to geriatric assessment (GA). All of the patients were stage III or IV at diagnosis; active disease was evident in 13 out of 29 elderly patients at the time of auto HSCT. As per outcomes, elderly lymphoma patients were safely and effectively treated with auto-HSCT. All patients showed an overall response. The patients were estimated to have a probability of 4-year progression-free survival and estimated overall survival of 37.5 % and 78.1 %, respectively.